Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non–Small-Cell Lung Cancer in China

Objective: Camrelizumab is the first domestic PD-1inhibitor approved to be combined with chemotherapy as a first-line therapy for advanced nonsquamous non–small-cell lung cancer (NSCLC) in China. The purpose of this study was to determine whether using camrelizumab in the first-line setting is cost-...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Liu, Zhou, Zhen, Zeng, Xiaohui, Tan, Chongqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593416/
https://www.ncbi.nlm.nih.gov/pubmed/34795580
http://dx.doi.org/10.3389/fphar.2021.728440

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593416/
https://www.ncbi.nlm.nih.gov/pubmed/34795580
http://dx.doi.org/10.3389/fphar.2021.728440

Ejemplares similares